Brodalumab: Looking beyond psoriasis

Brodalumab is a fully human monoclonal antibody that selectively targets interleukin-17 receptor A (IL-17RA), blocking the activity of pro-inflammatory IL-17 cytokines. Apart from psoriasis, brodalumab exhibits potential in managing hidradenitis suppurativa, pyoderma gangrenosum, and pityriasis rubra pilaris, with rapid and sustained lesional improvement. Besides, it has shown to have an acceptable safety profile. Although, not currently used in the treatment of bullous pemphigoid, lichen planus, and atopic dermatitis, brodalumab may elucidate efficacy for the same. The unique mechanism of brodalumab in blocking multiple IL-17 cytokines may contribute to its efficacy in patients who have failed other biologic therapies. Adverse effects observed with brodalumab are mild, although rarely serious alterations have been reported. While further research is needed in some areas, brodalumab represents an important therapeutic option for IL-17-mediated inflammatory skin disorders.